Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 6/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31688795 | 0.92 | CA12 (0.45) | TSHRCA12CA14CA2MAOA | |
| SCHEMBL12581334 | 0.92 | MAOA (0.41) | CA12CA14CA2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL13269542 | 0.90 | MAOA (0.40) | CA12CA14CA2MAOAMAOB | |
| SCHEMBL7432213 | 0.89 | TSHR (0.48) | TSHRCA12CA14CA2MAOA | |
| SCHEMBL3809747 | 0.89 | MAOA (0.39) | CA12CA14CA2MAOAMAOB | |
| SCHEMBL7429955 | 0.87 | TSHR (0.47) | TSHRCA12CA14CA2MAOA | |
| SCHEMBL19032764 | 0.86 | MAOA (0.49) | TSHRCA12CA14CA2MAOA | |
| SCHEMBL6535041 | 0.86 | MAOA (0.44) | CA12CA14CA2MAOAMAOB | |
| SCHEMBL756032 | 0.85 | MAOA (0.39) | TSHRCA12CA14CA2MAOA | |
| SCHEMBL753960 | 0.84 | ALDH1A1 (0.46) | TSHRMAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-3896056-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-10-20 | — | — | EP | disclosed |
| CN-113454058-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound comprising the same, and method for producing the same | 中外制药株式会社 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020122182-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | 中外製薬株式会社 | 2020-06-18 | — | — | WO | disclosed |
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| EP-1076663-B1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
| US-6369034-B1 | FOR THERAPY OF CANCER, RESTENOSIS, AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-04-09 | — | — | US | disclosed |
| EP-1076663-A1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055725-A1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | disclosed |
| EP-0384636-A1 | Pharmaceutically active compounds | FISONS plc (GB) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | VIP, DNPEP, HM13 | TSHR 3781/4885CA12 1136/4885CA14 1028/4885 |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP9, ADAM17, MMP3 | TSHR 2438/4885CA12 449/4885CA14 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.